Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sophia Sherman-Weber

Infectious Disease Mount Laurel, NJ Medical Doctor

NPI 1487681714 CMS profile 22196

1001 Briggs Rd Ste 250, Mount Laurel, NJ 08054

Open in the dashboard

General payments

$389

6 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sophia Sherman-Weber of Mount Laurel, NJ is reported in the CMS Open Payments database as having received $389 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26 1
2023 General $125 1
2020 General $114 2
2019 General $125 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sophia Sherman-Weber
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Sophia Sherman-Weber were reported at $26. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Sophia Sherman-Weber Infectious Disease median Middle half National median
2019 $125 $190 $60–$862 $163
2020 $114 $124 $32–$606 $114
2021 $0 $148 $38–$905 $132
2022 $0 $166 $50–$834 $149
2023 $125 $171 $57–$787 $160
2024 $0 $176 $52–$752 $164
2025 $26 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $163 4 payments
  2. ViiV Healthcare Company $125 1 payment
  3. Paratek Pharmaceuticals, Inc. $101 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $351 4 payments
  2. Education $38 2 payments
Products named General payments · program years 2019–2025
  1. RUKOBIA $125 1 payment
  2. ZINPLAVA $125 2 payments
  3. DIFICID $125 2 payments
  4. NUZYRA $101 1 payment
  5. ZERBAXA $38 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

137

Median for Infectious Disease: 268

Drug cost

$54,022

Median for Infectious Disease: $217,595

Branded share of claims

0%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Daptomycin Generic 17 $32,726
Meropenem Generic 34 $12,883
Cefepime Hcl Generic 23 $4,985
Vancomycin Hcl Generic 14 $2,738
Cefazolin Sodium Generic 20 $407
Doxycycline Hyclate Generic 14 $237
Mupirocin Generic 15 $45

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$126,447

Of which drugs: $4,017

Medicare patients

446

Average age 75

Services billed

39,559

225 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 49%
Ischemic heart disease 48%
Chronic kidney disease 45%
Heart failure 40%
Atrial fibrillation 37%
Depression 37%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, daptomycin, 1 mg J0878 Office 25 35,900 $1,727
Injection, ertapenem sodium, 500 mg J1335 Office 35 148 $1,339
Injection, ceftriaxone sodium, per 250 mg J0696 Office 43 868 $315

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record